An interventional study of Ropivacaine in Post Operative Pain, sponsored by Fayoum University Hospital. Recruiting at 1 site in Saudi Arabia. Open to participants aged 20 Years to 65 Years. Per ClinicalTrials.gov, last updated 2023-09-13.
Sponsored by Fayoum University Hospital · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 184 studies testing ropivacaine in Pain, Postoperative — 20 open to participants now, 22 under way, 2 of them phase 3. Ropivacaine · Pain, Postoperative.
Among the 184 studies testing ropivacaine in Pain, Postoperative, this one is the 56th largest by planned enrollment, is one of 8 that started in 2023, is one of 61 with no phase, reaches primary completion later than 1 of the 21 other live ones, and was the 166th registered.
5,680 studies on the registry are indexed under Pain, Postoperative; 1,243 are open to participants now.
Browse Pain, Postoperative studies →20 of the 184 studies testing ropivacaine in Pain, Postoperative are open now, in 10 countries. Recruiting first, the newest first:
Maternity Hospital - State Budgetary Institution of the Rostov Region, Taganrog · Sites in Russia
Ages 18–40 · Women only
Huazhong University of Science and Technology · Sites in China
Ages 18–80
Rutgers, The State University of New Jersey · Sites in United States
Ages 18+
Mount Sinai Hospital, Canada · Sites in Canada
Ages 18+ · Women only · Healthy volunteers
TLC Biopharmaceuticals, Inc. · Sites in United States
Ages 18–70
By country, each count listing its studies:
Ropivacaine: first FDA approval 1996 (NAROPIN). What it is approved for, and how studies give it, is on its page →
Of the 678 Pain, Postoperative studies recruiting now, 239 (35%) set no upper age limit and 329 (49%) stop at 75 or younger; 74 take children under 18; 129 take healthy volunteers.
This study: 20 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
184 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 12 · Phase 3 24 · Phase 4 84
First in 2003; this study’s year is marked. 8 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 90 is above the median of 75 across 4,859 interventional studies indexed under Pain, Postoperative.
Median enrollment 70 across the 184 interventional studies. Of the 125 that completed or were terminated, 32 (26%) have results posted.
This tab as a report to print or save as PDF → With an account.
6 of 184 have an industry lead sponsor. The 10 most frequent:
Fayoum University Hospital is the lead sponsor of 77 studies on the registry; 14 are open to participants now.
17 studies in Pain, Postoperative by Fayoum University Hospital: 4 open now, 4 under way, none of them phase 3. Of 11 finished, 0 (0%) have results posted.
Among the 17 studies in Pain, Postoperative by Fayoum University Hospital, this one is the 6th largest by planned enrollment, is the only one that started in 2023, is one of 14 with no phase, and was the 10th registered.
Fayoum University Hospital’s Pain, Postoperative studies by the year they started, since 2017.
6 of the studies testing ropivacaine in Pain, Postoperative that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03230565Stanford UniversityContinuous Infusions vs Scheduled Bolus Infusions | 2026-12 |
| NCT06189781University of California, Los AngelesPain Injection Versus Epidural Anesthesia for Hip Surgery in Pediatric Patients With Cerebral Palsy | 2026-12-30 |
| NCT07099222University of ArizonaEfficacy of Non-weight Based, Low Dose Dex-Dex Adjuncts in Prolonging Peripheral Nerve Blocks | 2026-12-31 |
| NCT07704970Huazhong University of Science and TechnologyQLESP Block for Pain Control in Robotic Partial Nephrectomy | 2027-02-28 |
| NCT07853482Maternity Hospital - State Budgetary Institution of the Rostov Region, TaganrogTAP vs. ESP Blocks for Post-Cesarean Analgesia | 2027-05-10 |
Add all 6 to your calendar (.ics) → With an account.
Among the 184 studies testing ropivacaine in Pain, Postoperative, from their registry updates:
Among Fayoum University Hospital’s 17 in Pain, Postoperative:
This tab as a report to print or save as PDF → With an account.
Background: Multimodal analgesia for control of postoperative pain in cardiac surgical patients helps in early recovery and ambulation. Pectoral nerve (PECS) block with ropivacaine is novel, less invasive regional analgesic technique with an effect comparable to paravertebral, and thoracic epidural analgesia.
Aim: The aim of this study is to assess the effect of dexmedetomidine as an adjuvant to ropivacaine on the quality and efficiency of the ultra-sound guided pectoralis nerve block in patients undergoing open heart surgery through midline sternotomy for fast-track anesthesia and postoperative analgesia.
In 2012 Blanco et al. [1] described the ultrasound technique for Pectoral nerve (PECS) block as a new, less invasive regional analgesic technique for breast surgeries.
PECS block includes PECS I and PECS II (modified PECS I) interfascial blocks. Since that time, PECS block has been used successfully with good results for a wide variety of surgeries on chest wall such as radical mastectomies, breast-conserving surgeries, breast implant placement, automated implantable cardioverter-defibrillator (AICD)/pacemaker placement, intercostal drainage tube placement, and rib fractures. [1] PECS I \& II blocks are considered very safe due to the lack of major neurovascular bundles surrounding the area of interest [2, 3].
In 2018 Kumar et al. [4] investigated the efficacy of ultrasound-guided bilateral PECS block for patients undergoing cardiac surgery through midline sternotomy approach. They concluded that Pecs block is technically simple, safe, and very effective technique and can be used as a part of multimodal analgesia in postoperative cardiac surgical patients for better patient comfort and satisfaction and also helps in superior pulmonary rehabilitation, thus assisting in better outcome. [4] With ultrasound guidance, this block has a short learning curve, and because it is superficial block, it is easier to apply, and this is one of the reasons for its increasing use and importance, and it is often performed instead of thoracic epidural block (TEA) and thoracic paravertebral block (TPVB). [4] The current data clearly demonstrates earlier extubation and reduced perioperative narcotic consumption [4-6], which are inherently beneficial for the patient. Adequate pain control is critical for respiratory mechanics and metabolic activity, especially for cardiac patients.
Compared with other regional anesthesia techniques, the ability to perform PECS block in the supine position is a critical advantage as it is convenient to place and should not impact the logistics of the operating room workflow. In addition, it has great potential as a postop analgesic option for cardiac surgeries, possibly as a rescue block. [4] Ropivacaine is a long-acting local anaesthetic agent that is less lipophilic than bupivacaine, and this reduced lipophilicity is associated with decreased potential for central nervous system toxicity and cardiotoxicity. [7] Dexmedetomidine is a potent and highly selective α2-adrenoreceptor agonist. It has sedative-hypnotic, anxiolytic, analgesic, anesthetic-reducing and local anesthetic effects. [8] The mechanism of action of dexmedetomidine for potentiation of local anesthetics may be through its central action, α-2 receptor-mediated vasoconstriction, attenuation of inflammatory responses, direct effect on peripheral nerves, or by increasing the activity-dependent hyperpolarization through blocking the hyperpolarization-activated cation (Ih) current. [9] The available preclinical and clinical data propose that the addition of dexmedetomidine with local anesthetics is well tolerated without signs of neurotoxicity. [10] In this study, we hypothesized that adding dexmedetomidine as an adjuvant to ropivacaine can result in prolongation of duration of anesthesia with improvement of the quality of postoperative analgesia of bilateral PECS block for patients undergoing cardiac surgery via midline sternotomy compared with using only plain ropivacaine.
Patients and Methods:
After approval of our local ethical committee, and based upon written informed consent, ninety patients, ASA physical statuses III or IV, undergoing either coronary artery bypass grafting (CABG) or valve surgeries through midline sternotomy will be enrolled in the study.
Inclusion criteria:
Exclusion criteria:
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
will not receive any regional anesthesia and only will receive fentanyl 1μg/kg/hr.
Drug: Ropivacaine
will receive 30 ml of 0.25% of plain ropivacaine for each side.
Drug: Ropivacaine
will receive 30 ml of 0.25% of ropivacaine + dexmedetomidine 0.5 μg/kg for each side.
Drug: Ropivacaine
dexmedetomidine
the total postoperative opioid consumption
the total postoperative opioid consumption
Time frame: the first 48 hours postoperative
Duration of mechanical ventilation
Duration of mechanical ventilation (day)
Time frame: the first 48 hours postoperative
Plan to share: No — no plane
Started Aug 2023 (actual). Primary completion is estimated for Aug 2024, 12 months after the start.
Of 2,113 non-industry interventional studies with no phase under Pain, Postoperative, half reached primary completion within 11 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 23. This study's planned 12 months is close to that.
Counting every sponsor, half of 2,126 studies reached it within 11 months; a quarter within 6 and three quarters within 23.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ropivacaine
Fayoum University Hospital